300584.SZ
Nanjing Hicin Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 32.79
−0.33%Sep 18, 2026, 13:28 UTC
Haichen Pharmaceutical plans to acquire the minority shareholders' equity in its controlling subsidiary.
Source:Sep 18, 2026, 09:42 UTC
Haisheng Pharmaceutical announced it will acquire the remaining 25% stake in its controlling subsidiary Anqing Huichen for 64.5083 million yuan plus 0 yuan, raising its holding from 75% to 100% and making Anqing Huichen a wholly owned subsidiary.
Aug 24, 2026, 10:13 UTC
Haishen Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 32.065 million yuan, up 9.97% year-on-year.